Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Fig. 3

Baseline-adjusted change in weight over 18 months in patients initiated on second-line therapies. Data are means ± SE. Data are from patients who had available weight measurements at each timepoint and at baseline, and who were on-treatment at each time-point (i.e. had not switched, intensified or ceased second-line treatment since the previous time-point). DPP-4i, dipeptidyl peptidase-4 inhibitor; MET, metformin; N, number of patients; SGLT-2i, sodium–glucose cotransporter 2 inhibitor; SE, standard error; SU, sulfonylurea. *Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies

Back to article page